Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NNMT | P40261 | 1/20 | 0.32 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL247841 | 0.79 | KDM4E (0.57) | GAAKDM4EMAPTLMNAMEN1 | |
| Water SCHEMBL6221139 | 0.79 | KDM4E (0.57) | GAAKDM4EMAPTLMNAMEN1 | |
| SCHEMBL29624542 | 0.79 | KDM4E (0.57) | GAAKDM4EMAPTLMNAMEN1 | |
| Hydrochloric Acid SCHEMBL29700837 | 0.78 | KDM4E (0.55) | GAAKDM4EMAPTLMNAMEN1 | |
| Hydrochloric Acid SCHEMBL21857700 | 0.78 | KDM4E (0.55) | GAAKDM4EMAPTLMNAMEN1 | |
| SCHEMBL4756265 | 0.73 | PTK2 (0.59) | GAAKDM4EMAPTMEN1KMT2A | |
| SCHEMBL11776219 | 0.73 | GRM5 (0.33) | — | |
| SCHEMBL2445812 | 0.71 | — | — | |
| SCHEMBL3959655 | 0.69 | P2RX7 (0.51) | GAAMAPTALDH1A1 | |
| SCHEMBL9551722 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130149239-A1 | 5-PYRROLIDINYLSULFONYL-ISATIN DERIVATIVES | UNIVERSITATSKLINIKUM MUNSTER (DE) | 2013-06-13 | — | — | US | claimed |
| US-8440841-B2 | 5-pyrrolidinylsulfonyl isatin derivatives | Universitätsklinikum Münster (DE) | 2013-05-14 | — | — | US | claimed |
| US-20090041664-A1 | 5-Pyrrolidinylsulfonyl Isatin Derivatives | UNIVERSITATSKLINIKUM MUNSTER (DE) | 2009-02-12 | — | — | US | claimed |
| EP-1841759-A2 | 5-PYRROLIDINYLSULFONYL ISATIN DERIVATIVES | Universitätsklinikum Münster (DE) | 2007-10-10 | — | — | EP | claimed |
| WO-2006074799-A2 | 5-PYRROLIDINYLSULFONYL ISATIN DERIVATIVES | Universitätsklinikum Münster (DE) | 2006-07-20 | — | — | WO | claimed |
| US-20130149239-A1 | 5-PYRROLIDINYLSULFONYL-ISATIN DERIVATIVES | UNIVERSITATSKLINIKUM MUNSTER (DE) | 2013-06-13 | — | — | US | disclosed |
| US-8440841-B2 | 5-pyrrolidinylsulfonyl isatin derivatives | Universitätsklinikum Münster (DE) | 2013-05-14 | — | — | US | disclosed |
| US-20090041664-A1 | 5-Pyrrolidinylsulfonyl Isatin Derivatives | UNIVERSITATSKLINIKUM MUNSTER (DE) | 2009-02-12 | — | — | US | disclosed |
| EP-1841759-A2 | 5-PYRROLIDINYLSULFONYL ISATIN DERIVATIVES | Universitätsklinikum Münster (DE) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006074799-A2 | 5-PYRROLIDINYLSULFONYL ISATIN DERIVATIVES | Universitätsklinikum Münster (DE) | 2006-07-20 | — | — | WO | disclosed |
| EP-1068222-A1 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION AND FOR IMAGING AND TREATMENT OF CANCER | Du Pont Pharmaceuticals Company (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999051628-A1 | RADIOPHARMACEUTICALS FOR IMAGING INFECTION AND INFLAMMATION AND FOR IMAGING AND TREATMENT OF CANCER | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130149239-A1 | 5-PYRROLIDINYLSULFONYL-ISATIN DERIVATIVES | CASP5, SLC1A5, CTSZ | GAA 2298/4885KDM4E 4132/4885MAPT 3084/4885 |
| US-20090041664-A1 | 5-Pyrrolidinylsulfonyl Isatin Derivatives | CASP5, CTSZ, CTSS | GAA 2120/4885KDM4E 4029/4885MAPT 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.